Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
SNAP25	6616	INCOBOTULINUMTOXINA	CHEMBL2108035	inhibitor	ChemblInteractions
SNAP25	6616	ABOBOTULINUMTOXINA	CHEMBL2108570	inhibitor	ChemblInteractions
SNAP25	6616	DIAZOXIDE	CHEMBL181		NCI	15752769
SNAP25	6616	BOTULINUM TOXIN TYPE A PURIFIED NEUROTOXIN COMPLEX	CHEMBL1201574	inhibitor	TdgClinicalTrial, ChemblInteractions, TEND, TTD

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
SNAP25	rs3746544	G	methylphenidate	efficacy	no	There were no significant genetic effects on ADHD symptoms as measured by the parent-teacher composite.	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele T.	17023870	1450372874
SNAP25	rs1051312	C	methylphenidate	efficacy	no	There were no significant genetic effects on ADHD symptoms as measured by the parent-teacher composite. Secondary analysis of the teacher CLAM-SKAMP composite approached significance for SNAP25 T1069C ( p = .05).	Allele C is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele T.	17023870	1450372908
SNAP25	rs3746544	G	methylphenidate	efficacy	no		Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele T.	19858760	1450372926
SNAP25	rs1051312	C	methylphenidate	efficacy	no		Allele C is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele T.	19858760	1450372933
SNAP25	rs3746544	GG + GT	methylphenidate	efficacy	yes	For the genetic component, in the CGI-S model, a dominant effect in SNAP25 rs3746544 was found with a significant improvement in the symptoms. Clinical Global Impression-Severity (CGI-S) scale and the Children’s Global Assessment Scale (CGAS).	Genotypes GG + GT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype TT.	28871191	1450376546
SNAP25	rs3746544	GT + TT	methylphenidate	efficacy	no	Good response group defined by K-ARS scores, 33.3% of the subjects with GG genotype showed a good response, whereas 74.7% of those with TT genotype and 72.5% of those with TG genotype showed good responses (P=0.034). When treatment response was defined as K-ARS and CGI-I, good response rate of each genotype was 22.2%, 65.8%, and 70.6% (P=0.018). Findings were not significant adjusting for multiple comparison.	Genotypes GT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype GG.	25229170	1450376889
SNAP25	rs3746544	TT	methylphenidate	efficacy	no		Genotype TT is not associated with response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity as compared to genotypes GG + GT.	23131881	981478844
SNAP25	rs8636	CT	amisulpride	efficacy	yes	This is the "overdominant model", the recessive model was not significant after correction (CT+TT vs CC). They did not show CT vs CC. (TT is low frequency) but additive model CC vs CT vs TT was also significant after correction. Response was measured by PANNS.	Genotype CT is associated with increased response to amisulpride in people with Schizophrenia as compared to genotypes CC + TT.	28947383	1449181943
SNAP25	rs363020	AA	methylphenidate	efficacy	no		Genotype AA is not associated with response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity as compared to genotypes AT + TT.	23131881	981478851